Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alumis Inc. stock logo
ALMS
Alumis
$4.45
-8.8%
$5.52
$3.18
$13.53
$210.13MN/A367,811 shs1.35 million shs
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$29.48
+2.1%
$28.08
$23.23
$42.29
$947.25M0.63427,338 shs268,741 shs
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$14.99
-0.1%
$14.46
$10.91
$40.26
$903.54M2.78612,863 shs435,228 shs
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$5.94
-0.2%
$6.86
$4.25
$16.74
$917.10M-0.921.29 million shs1.06 million shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alumis Inc. stock logo
ALMS
Alumis
-8.81%-8.81%+3.97%-2.63%+444,999,900.00%
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
+2.15%-1.60%+10.04%+3.99%-13.93%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-0.13%-2.66%+6.09%-21.11%-54.55%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-0.17%-9.17%-11.74%-43.96%-4.50%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alumis Inc. stock logo
ALMS
Alumis
2.2855 of 5 stars
3.60.00.00.02.81.70.6
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
4.0429 of 5 stars
3.40.00.03.04.00.82.5
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
1.9887 of 5 stars
3.60.00.00.02.62.50.6
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
4.4012 of 5 stars
3.51.00.04.83.64.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alumis Inc. stock logo
ALMS
Alumis
3.22
Buy$24.86458.59% Upside
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.80
Moderate Buy$43.8048.58% Upside
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
3.25
Buy$53.40256.24% Upside
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
3.00
Buy$21.17256.34% Upside

Current Analyst Ratings Breakdown

Latest ALMS, WVE, COLL, and SYRE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Alumis Inc. stock logo
ALMS
Alumis
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$26.00 ➝ $25.00
5/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral$36.00 ➝ $37.00
5/5/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$65.00
4/30/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$14.00 ➝ $14.00
4/29/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
4/22/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/9/2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$46.00 ➝ $46.00
4/8/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/8/2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$45.00
4/8/2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$18.00
3/26/2025
Alumis Inc. stock logo
ALMS
Alumis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alumis Inc. stock logo
ALMS
Alumis
$17.39M12.08N/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$664.28M1.43$10.68 per share2.76$5.99 per share4.92
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
$890K1,015.21N/AN/A($0.22) per share-68.14
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
$104.94M8.72N/AN/A$0.40 per share14.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alumis Inc. stock logo
ALMS
Alumis
N/AN/A0.00N/AN/AN/AN/AN/A6/18/2025 (Estimated)
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$48.15M$1.2212.714.90N/A14.78%104.67%18.38%8/14/2025 (Estimated)
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$338.79M-$3.77N/AN/AN/AN/A-210.01%-44.40%8/6/2025 (Estimated)
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$57.51M-$0.84N/AN/AN/A-66.50%-280.57%-52.90%8/14/2025 (Estimated)

Latest ALMS, WVE, COLL, and SYRE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/18/2025N/A
Alumis Inc. stock logo
ALMS
Alumis
-$1.47N/AN/AN/AN/AN/A
5/14/2025Q1 2025
Alumis Inc. stock logo
ALMS
Alumis
-$1.47-$1.82-$0.35-$1.82N/AN/A
5/8/2025Q1 2025
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
$1.50$1.49-$0.01$0.07$174.96 million$177.76 million
5/8/2025Q1 2025
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
-$0.76-$0.74+$0.02-$0.74N/AN/A
5/8/2025Q1 2025
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.27-$0.29-$0.02-$0.29$11.65 million$9.18 million
3/4/2025Q4 2024
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
-$0.17$0.17+$0.34$0.17$25.60 million$83.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alumis Inc. stock logo
ALMS
Alumis
N/AN/AN/AN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/AN/AN/AN/AN/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/AN/AN/AN/AN/A
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alumis Inc. stock logo
ALMS
Alumis
N/A
11.26
11.26
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
3.43
0.97
0.88
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
N/A
7.32
7.32
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
N/A
1.90
1.90

Institutional Ownership

CompanyInstitutional Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
N/A
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
80.39%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
89.73%

Insider Ownership

CompanyInsider Ownership
Alumis Inc. stock logo
ALMS
Alumis
N/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
2.51%
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
15.43%
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
29.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alumis Inc. stock logo
ALMS
Alumis
N/A47.22 millionN/AN/A
Collegium Pharmaceutical, Inc. stock logo
COLL
Collegium Pharmaceutical
21032.13 million30.97 millionOptionable
Spyre Therapeutics, Inc. stock logo
SYRE
Spyre Therapeutics
7360.28 million48.24 millionOptionable
Wave Life Sciences Ltd. stock logo
WVE
Wave Life Sciences
240154.13 million108.14 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Alumis stock logo

Alumis NASDAQ:ALMS

$4.45 -0.43 (-8.81%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.49 +0.04 (+0.79%)
As of 05/27/2025 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words "allumer"-French for illuminate-and "immunis"-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in an additional Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE), for which we expect to report results in 2026. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024. We utilize our proprietary precision data analytics platform, biological insights and team of experienced research and development experts to deepen our understanding of disease pathologies, accelerate research and development and increase the probability of clinical success. Our collective insights informed our selection of TYK2 as the target for our two lead programs. Beyond TYK2, our proprietary precision data analytics platform and drug discovery expertise have led to the identification of additional preclinical programs that exemplify our precision approach. We recognize that patients living with immune-mediated diseases need alternatives to currently available therapies. Despite recent advances and innovations in the treatment of immune-mediated diseases, many patients continue to suffer, cycling through currently approved therapies while looking for a solution that alleviates the debilitating impact of their disease without life-limiting side effects. Addressing the needs of these patients is why we exist. We are pioneering a precision approach that leverages insights derived from powerful data analytics to select the right target, right molecule, right indication, right patient, right endpoint and right combination to dramatically improve patient outcomes. We believe that combining our insights with an integrated approach to drug development will produce the next generation of treatments to address immune dysfunction. We were founded in January 2021 as a Delaware corporation under the name FL2021-001, Inc. We changed our name to Esker Therapeutics, Inc. in March 2021, and subsequently to Alumis Inc. in January 2022. Our principal executive offices are located at 280 East Grand Avenue, South San Francisco, California.

Collegium Pharmaceutical stock logo

Collegium Pharmaceutical NASDAQ:COLL

$29.48 +0.62 (+2.15%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$31.09 +1.61 (+5.46%)
As of 05/27/2025 07:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

Spyre Therapeutics stock logo

Spyre Therapeutics NASDAQ:SYRE

$14.99 -0.02 (-0.13%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$15.00 +0.02 (+0.10%)
As of 05/27/2025 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Wave Life Sciences stock logo

Wave Life Sciences NASDAQ:WVE

$5.94 -0.01 (-0.17%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$6.23 +0.29 (+4.88%)
As of 05/27/2025 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington's disease (HD). The company has collaboration agreements with GlaxoSmithKline for the research, development, and commercialization of oligonucleotide therapeutics; Takeda Pharmaceutical Company Limited for the research, development, and commercialization of oligonucleotide therapeutics for disorders of the Central Nervous System; and Asuragen, Inc. for the development and potential commercialization of companion diagnostics for investigational allele-selective therapeutic programs targeting HD. Wave Life Sciences Ltd. was incorporated in 2012 and is based in Singapore.